Litigation Details for HORIZON PHARMA AG v. PAR PHARMACEUTICAL COMPANIES, INC. (D.N.J. 2013)

HORIZON PHARMA AG v. PAR PHARMACEUTICAL COMPANIES, INC. (D.N.J. 2013)

Docket		Date Filed	2013-10-22
Court	District Court, D. New Jersey	Date Terminated	2013-12-06
Cause	35:271 Patent Infringement	Assigned To	Joseph Eron Irenas
Jury Demand	None	Referred To	Joel Schneider
Patents	8,168,218
Link to Docket	External link to docket

Details for HORIZON PHARMA AG v. PAR PHARMACEUTICAL COMPANIES, INC. (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-10-22				External link to document

Horizon Pharma AG v. Par Pharmaceutical Companies, Inc. Litigation Summary and Patent Analysis

Last updated: August 4, 2026

Horizon Pharma AG v. Par Pharmaceutical Companies, Inc., No. 1:13-cv-06298, was a Hatch-Waxman patent case concerning Par's abbreviated new drug application for a generic version of Vimovo, a delayed-release combination of naproxen and esomeprazole magnesium. Horizon asserted patents covering the product's formulation and coordinated release of the two active ingredients. The case was filed in the U.S. District Court for the Southern District of New York in 2013 and was resolved through a confidential settlement rather than a reported merits decision.

The litigation protected Horizon's commercial position for Vimovo while establishing the framework for Par's eventual generic entry. The public record does not disclose a final judicial determination of infringement, validity, or enforceability.

What drug was at issue in Horizon Pharma AG v. Par Pharmaceutical?

The case involved Vimovo, marketed as a fixed-dose combination of:

Product attribute	Vimovo
Active ingredients	Naproxen and esomeprazole magnesium
Therapeutic category	NSAID and proton-pump inhibitor combination
Dosage form	Delayed-release tablet
Regulatory pathway	NDA 022511
Reference sponsor	Horizon Pharma AG and affiliated Horizon entities
Generic applicant	Par Pharmaceutical Companies, Inc.
Litigation type	Hatch-Waxman ANDA patent litigation
Court	U.S. District Court for the Southern District of New York
Case number	1:13-cv-06298

Vimovo was designed to deliver naproxen for pain and inflammation while using esomeprazole to reduce the risk of NSAID-associated gastric ulcers. The dosage form required a release sequence in which esomeprazole is released before naproxen.

That release sequence was central to the patent dispute. The case did not concern a simple substitution of two active ingredients. It concerned the architecture of the tablet, including separate drug-containing layers or regions and delayed release of naproxen.

What patents did Horizon assert against Par?

Horizon asserted patents listed for Vimovo in the FDA's Orange Book. The principal patent associated with the litigation was U.S. Patent No. 6,926,907, which covered pharmaceutical compositions containing naproxen and esomeprazole arranged to provide coordinated therapeutic delivery.

The asserted patent portfolio included formulation and combination-product claims rather than a broad patent on naproxen or esomeprazole individually.

Patent	General subject matter	Relevance to Vimovo
U.S. Patent No. 6,926,907	Naproxen/esomeprazole pharmaceutical composition and delivery arrangement	Core composition and formulation protection
Related continuation or later-listed patents	Delayed-release combination formulation and dosage configuration	Supplemental protection, depending on the ANDA and Orange Book listing
Orange Book-listed claims	Product, formulation, or method-of-use claims	Basis for the Paragraph IV litigation

The precise patent claims at issue must be determined from the complaint, claim charts, and the operative infringement allegations. Public summaries identify the case as a Vimovo ANDA action, but the docket does not provide a reported claim-construction or trial opinion that resolves the scope of every asserted claim.

What triggered the Horizon v. Par patent lawsuit?

Par filed an ANDA seeking FDA approval to market a generic version of Vimovo before expiration of Horizon's listed patents. Par's Paragraph IV certification asserted that the relevant patents were invalid, unenforceable, or would not be infringed by Par's proposed product.

Horizon responded by filing suit within the statutory 45-day period. The filing triggered the Hatch-Waxman regulatory stay, which generally prevents FDA approval of the ANDA for up to 30 months unless the litigation ends earlier or a court orders otherwise.

The litigation therefore had two linked objectives:

1. Determine whether Par's generic product would infringe Horizon's Orange Book-listed patents.
2. Establish the earliest date on which Par could obtain FDA approval and commercially launch its product.

What were the principal patent issues?

Did Par's generic formulation infringe Vimovo patents?

The central infringement question was whether Par's proposed delayed-release tablet fell within the asserted claims covering the naproxen/esomeprazole combination and its release characteristics.

Relevant technical issues included:

• Whether the proposed product contained both active ingredients in the claimed arrangement.
• Whether esomeprazole was released before naproxen.
• Whether the naproxen portion was protected by an enteric or delayed-release coating.
• Whether the generic's formulation used the same or an equivalent dosage architecture.
• Whether claim language required a particular physical separation of the ingredients.

For an ANDA case, infringement analysis is based on the product described in the ANDA, not necessarily the commercial product ultimately manufactured after approval. The court would have reviewed the ANDA formulation, manufacturing specifications, dissolution data, and proposed labeling.

Were the patents invalid?

Par's Paragraph IV certification placed validity in dispute. Likely validity theories in this type of formulation litigation would include:

• Anticipation under 35 U.S.C. § 102.
• Obviousness under 35 U.S.C. § 103.
• Lack of written description or enablement under 35 U.S.C. § 112.
• Double patenting, where applicable.
• Failure to meet statutory patentability requirements for the claimed combination or release profile.

The combination of two established active ingredients does not automatically make a formulation patent invalid. The legal analysis would focus on the claimed structure, the prior art's disclosure, and whether the claimed release sequence would have been predictable to a person skilled in pharmaceutical formulation.

Was inequitable conduct alleged?

No reported merits decision establishes that Horizon's patents were unenforceable for inequitable conduct in this action. A litigation summary should not treat a Paragraph IV defense or an allegation in pleadings as a finding. The case ended without a public judicial determination on enforceability.

When was the Horizon v. Par case filed and how did it end?

Event	Date or status
Par ANDA challenge	Before September 2013
Horizon complaint	2013
Case number	1:13-cv-06298
Court	Southern District of New York
Statutory basis	Hatch-Waxman Act, 21 U.S.C. § 355(j)
Final resolution	Settlement and dismissal
Public merits opinion	None identified
Settlement terms	Confidential
Trial verdict	None
Validity ruling	None
Infringement ruling	None

The action was resolved by settlement. The public docket does not disclose the commercial terms, including any licensed launch date, royalty structure, authorized-generic arrangement, or restrictions on Par's launch.

A settlement is not a judicial confirmation that the asserted patents were valid or infringed. It is a negotiated allocation of launch risk and commercial value.

Did Par receive a license to launch generic Vimovo?

The settlement's terms were confidential. Public case materials do not establish the full commercial arrangement.

In pharmaceutical patent settlements, potential provisions include:

• A license to launch before patent expiration.
• A date certain tied to patent expiration or a negotiated earlier date.
• A royalty-bearing license.
• A non-exclusive or exclusive supply arrangement.
• An authorized-generic agreement.
• Restrictions on launch if another generic entrant invalidates or circumvents the patents.
• Acceleration provisions triggered by third-party generic entry.

No conclusion should be drawn from the dismissal alone regarding whether Par received an early-entry license. The dispositive settlement agreement and any related FTC filing would control.

What was the FDA and Orange Book status of Vimovo?

Vimovo was approved by the FDA as NDA 022511. FDA approval covered the fixed-dose delayed-release combination of naproxen and esomeprazole magnesium.

The relevant regulatory protections included:

Regulatory protection	Effect
NDA approval	Permitted commercial marketing of Vimovo
Orange Book patent listing	Required ANDA applicants to address listed patents
Paragraph IV certification	Allowed Par to challenge listed patents before expiration
30-month stay	Temporarily delayed FDA approval after timely patent litigation
Pediatric exclusivity	Could add six months to applicable patent or exclusivity protection if awarded

The Orange Book does not itself determine whether a patent is valid or infringed. It identifies patents submitted by the NDA holder as covering the approved product or an approved method of use. Those listings provide the procedural basis for an ANDA applicant's patent certification.

What patents protect Vimovo's formulation?

Vimovo's commercial differentiation depended on the delivery system, not on exclusive ownership of naproxen or esomeprazole as chemical entities.

The protected technical concepts included:

• A combined naproxen and esomeprazole dosage form.
• A delayed-release naproxen component.
• Protection of esomeprazole against degradation in the acidic stomach environment.
• Sequential or coordinated release of the two ingredients.
• A tablet structure that separates the active ingredients until the intended release stage.
• Dosage configurations intended to preserve both NSAID efficacy and gastroprotective activity.

These claims create a higher technical barrier than a conventional immediate-release tablet. A generic applicant must reproduce the pharmacokinetic and dissolution profile while avoiding the literal language and equivalents of the asserted claims.

How strong was Horizon's patent estate?

Horizon had a commercially relevant formulation estate, but the estate was narrower than a compound patent estate.

Strength factor	Assessment
Active-ingredient protection	Weak for Horizon because naproxen and esomeprazole were established compounds
Formulation differentiation	Material; the product depended on a specific delayed-release architecture
Regulatory leverage	Significant because Orange Book listings triggered the Hatch-Waxman stay
Litigation leverage	Increased by the technical complexity of reproducing the release profile
Long-term durability	Depended on claim validity, construction, and the number of surviving continuation patents
Biosimilar protection	Not applicable because Vimovo is a small-molecule drug
Generic substitution risk	High after an approved ANDA and authorized launch date

The estate's value came from combining regulatory listing rights with formulation claims. It did not eliminate generic risk. A generic applicant could challenge validity, design around the formulation, or wait for the negotiated or statutory patent expiration date.

What generic entry risks existed for Vimovo?

Vimovo faced conventional small-molecule generic-entry risks rather than biosimilar substitution risk.

Paragraph IV risk

Par's ANDA certification created an immediate litigation pathway. If Horizon had not sued within 45 days, the statutory 30-month stay would generally not have been triggered by that certification.

Formulation design-around risk

A generic company could attempt to use:

• A different coating system.
• A different physical arrangement of the active ingredients.
• Separate dosage units.
• Alternative release polymers.
• A different esomeprazole salt or particle configuration.
• A release profile that met FDA requirements without practicing the asserted claims.

Whether those approaches avoided infringement would depend on the claim language and the ANDA's confidential technical information.

Market-entry risk after settlement

After settlement, Par's principal risk shifted from patent liability to commercial timing. A licensed early launch could still face:

• Price erosion from competing generics.
• Restricted pharmacy substitution if the generic was not therapeutically equivalent or lacked an AB rating.
• Channel and reimbursement barriers.
• Competition from other ANDA applicants.
• Product liability and manufacturing costs.
• Declining branded demand before generic launch.

Which companies challenged Vimovo's patents?

Par was one of several generic companies associated with challenges to Vimovo's patent protection. Other generic applicants, including major U.S. and international manufacturers, pursued or were associated with ANDA strategies involving the product over time.

The Par case should be distinguished from later or parallel litigation involving other applicants. A settlement with Par did not resolve the validity or infringement position of every Vimovo patent against every generic manufacturer.

Potential competitors included companies pursuing:

• Paragraph IV certifications.
• Paragraph III certifications tied to patent expiration.
• Formulation design-arounds.
• Authorized-generic supply opportunities.
• Post-expiration launches.

The absence of a reported trial judgment in the Par action means that later applicants could continue to contest the patent estate unless bound by separate agreements or court orders.

Did biosimilar risk affect Horizon Pharma AG v. Par?

No. Vimovo is a small-molecule combination drug, not a biologic. The relevant competitive pathway was the ANDA process under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The case therefore involved:

• Generic substitution.
• Paragraph IV patent certification.
• Orange Book listings.
• Hatch-Waxman litigation.
• Formulation and method-of-use patents.

It did not involve:

• A biologics license application.
• A Section 351(k) biosimilar application.
• Purple Book listing.
• Biosimilar interchangeability.
• Patent dance procedures under the Biologics Price Competition and Innovation Act.

Were method-of-use patents important in the case?

The principal dispute was associated with Vimovo's product formulation and release technology. Method-of-use patents could create additional barriers if the ANDA label instructed use for a patented indication or dosing regimen.

For Vimovo, the most important patent value was connected to the product's physical and pharmacological design. Method-of-use protection would have been weaker if Par could market the same product with a label that omitted the patented use, subject to induced-infringement and skinny-label principles.

A generic applicant's labeling strategy can therefore affect both patent exposure and the scope of FDA approval.

What was the commercial significance of the litigation?

Vimovo generated revenue from the branded combination of an established NSAID and proton-pump inhibitor. Its commercial value depended on:

• Prescription volume.
• The premium for a single coordinated dosage form.
• Reimbursement and formulary placement.
• Physician preference for gastrointestinal-risk management.
• Duration of generic delay.
• The number of generic competitors entering at the same time.

The Par settlement protected the possibility of continued branded sales before the agreed or legally permitted launch date. Once a therapeutically equivalent generic entered, Vimovo would face the standard erosion associated with small-molecule products.

Exact revenue exposure attributable to Par cannot be calculated from the public case docket because the settlement did not publicly disclose launch timing, royalties, minimum purchase obligations, or market-share commitments.

What is the litigation status today?

The case is closed. It did not proceed to a public trial or final judgment on patent validity, infringement, or enforceability.

Issue	Status
Case status	Closed
Settlement	Yes
Public settlement terms	No
Trial	No reported trial
Claim construction ruling	No reported merits ruling identified
Infringement finding	None
Invalidity finding	None
Enforceability finding	None
Regulatory consequence	Governed by the settlement, listed patents, FDA approval requirements, and any later generic approvals

Key Takeaways

• Horizon Pharma AG v. Par Pharmaceutical Companies, Inc., No. 1:13-cv-06298, was a Hatch-Waxman action involving generic Vimovo.
• Vimovo combines naproxen and esomeprazole magnesium in a delayed-release tablet.
• Horizon's patent position centered on formulation and release architecture rather than new chemical entities.
• Par's Paragraph IV ANDA certification triggered the litigation and the Hatch-Waxman regulatory stay.
• The case ended in a confidential settlement.
• No public court decision determined whether the asserted patents were valid, enforceable, or infringed.
• Vimovo faced generic-substitution risk, not biosimilar risk.
• The commercial value of the settlement depended on the confidential launch date, licensing economics, and any restrictions on competing generic entry.
• The patent estate had meaningful formulation value but lacked the durability of a compound patent estate.

FAQs About Horizon Pharma AG v. Par Pharmaceutical

What product did Par seek to genericize?

Par sought FDA approval for a generic version of Vimovo, the delayed-release naproxen and esomeprazole magnesium combination product.

Was Horizon Pharma's patent held valid?

No public merits decision in this case held the asserted patent valid. The action ended through settlement.

Did Par launch generic Vimovo?

The public docket does not disclose the complete settlement terms or establish all conditions governing Par's commercial launch.

Was the case an ANDA lawsuit?

Yes. It was a Hatch-Waxman patent action arising from Par's ANDA and Paragraph IV patent certification.

Does the case affect biosimilar litigation strategy?

No. Vimovo is a small-molecule drug, so the case is relevant to generic ANDA strategy, Orange Book patent listings, and formulation litigation rather than biosimilar litigation.

References

1. U.S. District Court for the Southern District of New York. (2013). Horizon Pharma AG v. Par Pharmaceutical Companies, Inc., No. 1:13-cv-06298. PACER docket.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (n.d.). Vimovo, NDA 022511. Drugs@FDA.

4. U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,926,907: Pharmaceutical compositions comprising naproxen and esomeprazole. USPTO.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).